

State of Oklahoma SoonerCare Nerlynx[®] (Neratinib) Prior Authorization Form

Member Name:	Date of Birth:	Member ID#:
	Drug Information	
Pharmacy Billing (NDC:) Start Date (or date of next dose):	
Dose:	Regimen:	
	Billing Provider Informat	tion
Pharmacy NPI:	Pharmacy Name:	:
Pharmacy Phone:	Pharmacy Fax:	
	Prescriber Information	n
Prescriber NPI:	Prescriber Name:	
Prescriber Phone:	Prescriber Fax:	Specialty:
	Criteria	
B. Does member h cancer? Yes C. Is neratinib to form Recurrent or Metas A. Does member h B. Does member h C. Will neratinib be D. If member has h paclitaxel? Yes If answer is none of	ollow adjuvant trastuzumab-based thera static Breast Cancer have recurrent or metastatic breast cancer have HER2-overexpressed breast cancer e used in combination with capecitabine brain metastases, will neratinib be used No	2 (HER2)-overexpressed breast apy? Yes No cer? Yes No er? Yes No in combination with capecitabine or sis:
Has the member experience	evidence of progressive disease while enced adverse drug reactions related to se reactions:	neratinib therapy? Yes No
the best of my knowledge		ate:d all information is true and correct to ecessary. Failure to complete this form in full will

PLEASE PROVIDE THE INFORMATION REQUESTED AND RETURN TO:

University of Oklahoma College of Pharmacy Pharmacy Management Consultants Product Based Prior Authorization Unit

> Fax: 1-800-224-4014 Phone: 1-800-522-0114 Option 4

CONFIDENTIALITY NOTICE

This document, including any attachments, contains information which is confidential or privileged. If you are not the intended recipient, be aware that any disclosure, copying, distribution, or use of the contents of this information is prohibited. If you have received this document in error, please notify the sender immediately by telephone to arrange for the return of the transmitted documents or to verify their destruction.